A person experienced severe sexual side effects, including loss of libido and erectile dysfunction, after using finasteride and dutasteride for hair loss. They stopped the medications and sought advice, but recovery was slow and uncertain.
Fluridil is hard to obtain and only available in Slovakia and Czechia, with no systemic side effects but possibly limited effectiveness compared to finasteride. The original poster is using finasteride and minoxidil without success and is considering trying fluridil despite its cost.
The user experienced temple recession, shedding, and acne while on 0.5mg dutasteride, 1.25mg finasteride every other day, and 5mg oral minoxidil daily. They are considering switching treatments due to worsening symptoms and are contemplating using a topical anti-androgen like RU58841.
The conversation discusses avoiding caffeine after Platelet-Rich Plasma (PRP) treatment for hair loss because caffeine is a vasoconstrictor, which can reduce blood flow and hinder the healing process that PRP aims to promote.
The user experienced severe side effects from finasteride and is considering a combination therapy including Minoxidil, Tretinoin, microneedling, caffeine, and other ingredients. They are also thinking about adding red light therapy and microneedling once per week.
Quitting smoking and vaping, along with taking spirulina, improved hair thickness for some users. Others noted that smoking, vaping, and drinking may contribute to hair thinning.
The conversation discusses various treatments for hair loss, including finasteride, minoxidil, dutasteride, microneedling, and checking for nutrient deficiencies. Some users suggest adding hydrocortisone butyrate, low-dose progesterone, or tretinoin to treatment regimens, while others recommend cosmetic solutions like Toppik hair fibers or shaving the head.
A user is trying fluridil/topilutamide for hair loss and experiencing side effects like pain in the testicles and genital discomfort. They previously had adverse effects with finasteride, dutasteride, and RU58841, and are considering other treatments like topical dutasteride and spironolactone for maintenance before a hair transplant.
The user experienced severe hair loss, itchy scalp, and skin issues after trying no-shampoo, and wonders if it's male pattern baldness or an immune issue. They have a history of eczema, dermatitis, and jock itch, and have tried various treatments like coconut oil, peppermint, pumpkin seed, and onion.
A user experienced a "watery belly" and cellulite after starting finasteride, despite maintaining a disciplined fitness routine. Others suggest checking hormone levels, as changes in DHT and estrogen could affect fat metabolism, but age might also be a factor.
Minoxidil can inhibit collagen production, potentially causing premature aging. The user is inquiring if Vitamin C serum or derma rolling can counteract this effect.
RU58841 from Amazon is unreliable, with users reporting no benefits and side effects like eye swelling and chest pain. Rudirect is recommended for purchasing in Europe.
Winlevi (clascoterone), a DHT blocker, is being considered for hair loss treatment, though it's primarily an acne medication. Users discuss its potential effectiveness and note it may only work for a short time.
The conversation discusses the struggle with diffuse hair thinning and the effectiveness of treatments like finasteride, minoxidil, and RU58841. Users share experiences of hair thickening and shedding stopping with these treatments, but results vary and some are skeptical.
The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.
The user is experiencing diffuse hair thinning despite using finasteride and oral minoxidil, with no hairline recession or bald spots. Suggestions include checking for telogen effluvium, considering a JAK inhibitor for potential autoimmune issues, and conducting further tests to rule out other causes.
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
Adding non-prescription topicals like alfatradiol and Zix to a standard fin/min/niz regimen may help with scalp inflammation and shedding, but their long-term effectiveness varies. Zix is recommended for reducing scalp inflammation and enhancing the effectiveness of other treatments.
The conversation discusses disappointment in Verteporfin for hair loss treatment, with a mention of an upcoming trial by Dr. Bisanga. No specific treatments were confirmed as used by the original poster.
Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.
A male in his early 20s with CCCA (scarring alopecia) started treatment with Finasteride, Fluocinolone, and Doxycycline. Steroid injections were suggested but not yet done.
User experienced hair growth with finasteride and minoxidil, but after using tretinoin, faced aggressive thinning and hair loss. They plan to stop tretinoin for two months to see if the problem improves.
Dr. Bloxham's 9-month update on FUT scar revision with Verteporfin shows promising results. Excitement is high for FUE, which appears highly effective based on Dr. Barghouthi's findings.
The conversation discusses the potential use of verteporfin for hair loss treatment, with one user mentioning their surgeon's interest in trying it and another noting its research status and clinical use as a YAP inhibitor. Some users debate the market size, availability of generics, and the optimism in the hair loss community regarding new treatments.
Dr. Bloxham's trial is testing verteporfin on hair transplant patients to see if it can improve hair regrowth in treated areas. People are discussing the potential for follicle regeneration, expected results timeline, and concerns about side effects like cancer.
The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.
Verteporfin may improve hair transplant outcomes and reduce scarring, potentially allowing patients to avoid finasteride. Dr. Barghouthi seeks collaborations, volunteers, and financial support for research on verteporfin.org.